OnKure Therapeutics, Inc. (OKUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has a cash flow conversion efficiency ratio of -0.196x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.04 Million) by net assets ($66.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OnKure Therapeutics, Inc. balance sheet independence to measure how much of total assets are equity-financed.
OnKure Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OnKure Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OnKure Therapeutics, Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
OnKure Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kutcho Copper Corp
V:KC
|
-0.010x |
|
Canterra Minerals Corporation
V:CTM
|
-0.091x |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
0.102x |
|
Metrod Holdings Bhd
KLSE:6149
|
0.290x |
|
Zhong An Group Limited
F:35Z
|
0.005x |
|
Polarx Ltd
AU:PXX
|
0.000x |
|
Laird Superfood Inc
NYSE MKT:LSF
|
0.006x |
|
Phaos Technology Holdings (Cayman) Limited
NYSE MKT:POAS
|
N/A |
Annual Cash Flow Conversion Efficiency for OnKure Therapeutics, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of OnKure Therapeutics, Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see OnKure Therapeutics, Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $103.83 Million | $-51.12 Million | -0.492x | -245.14% |
| 2023-12-31 | $-101.84 Million | $-34.55 Million | 0.339x | -31.51% |
| 2022-12-31 | $-54.42 Million | $-26.95 Million | 0.495x | +291.96% |
| 2021-12-31 | $147.21 Million | $-37.98 Million | -0.258x | -158.62% |
| 2020-12-31 | $-42.12 Million | $-18.54 Million | 0.440x | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, includin… Read more